The Experts below are selected from a list of 46368 Experts worldwide ranked by ideXlab platform
Christopher G. Goetz - One of the best experts on this subject based on the ideXlab platform.
-
Movement Disorder society criteria for clinically established early parkinson s disease
Movement Disorders, 2018Co-Authors: Daniela Berg, Christopher G. Goetz, Anthony E Lang, Charles H Adler, Bastiaan R Bloem, Piu Chan, Thomas Gasser, Glenda M Halliday, Simon J G Lewis, Inga LiepeltscarfoneAbstract:Author(s): Berg, Daniela; Adler, Charles H; Bloem, Bastiaan R; Chan, Piu; Gasser, Thomas; Goetz, Christopher G; Halliday, Glenda; Lang, Anthony E; Lewis, Simon; Li, Yuan; Liepelt-Scarfone, Inga; Litvan, Irene; Marek, Kenneth; Maetzler, Corina; Mi, Taomian; Obeso, Jose; Oertel, Wolfgang; Olanow, C Warren; Poewe, Werner; Rios-Romenets, Silvia; Schaffer, Eva; Seppi, Klaus; Heim, Beatrice; Slow, Elizabeth; Stern, Matthew; Bledsoe, Ian O; Deuschl, Gunther; Postuma, Ronald B | Abstract: BACKGROUND:In 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies suggest high accuracy, one unmet need is for highly specific criteria for clinical trials in early/de novo PD. OBJECTIVES:The objective of this study was to generate and test a PD diagnostic criteria termed "clinically established early PD." METHODS:We modified the Movement Disorder Society criteria to increase specificity for early PD by removing all disease duration components and changing red flags to absolute exclusions. We then estimated the sensitivity/specificity of clinically established early PD criteria in patients with disease duration l5 years, selected from a 626-patient validation study. RESULTS:After documentation of parkinsonism, 18 individual exclusion criteria are assessed that preclude the diagnosis of "clinically established early PD." Among 212 PD and 152 non-PD patients, the estimated specificity was 95.4%, with 69.8% sensitivity. CONCLUSIONS:We describe high-specificity criteria for de novo PD, which are freely available for use in clinical trials. © 2018 International Parkinson and Movement Disorder Society.
-
Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing.
Movement Disorders, 2014Co-Authors: Brandon R. Barton, Bruno Dubois, Bryan Bernard, Virginie Czernecki, Jennifer G. Goldman, Glenn T. Stebbins, Christopher G. GoetzAbstract:The objective of our study was to compare Movement Disorder Society Task Force criteria for diagnosis of Parkinson's disease dementia (PDD) with the gold standard of traditional neuropsychological testing. A short checklist (Level I) and a protocol of neuropsychological tests (Level II) have been proposed by a Movement Disorder Society Task Force but not fully validated in clinical practice. Ninety-one Parkinson's disease (PD) subjects were categorized as having dementia or no dementia based on a battery of neuropsychological test results and clinical judgment. The isolated components needed for Level I and Level II diagnoses were then culled from the neuropsychological evaluations and independently used to designate PDD. Compared with traditional neuropsychological testing, the sensitivity and specificity of Level I criteria for PDD was 66.7% and 98.8%, and for Level II criteria 100% and 92.7%, respectively. Using Level II criteria, 6 additional subjects were diagnosed with PDD that were classified as having no dementia when full neuropsychological data were used for the diagnosis. These 6 subjects had more education years and were less impaired on cognitive tests. The Movement Disorder Society's Level II criteria more frequently classify subjects with PDD than does traditional neuropsychological testing. Whereas Level II criteria may overclassify subjects as having PDD, they are very accurate in ruling out dementia. Movement Disorder Society's criteria are practical and timesaving, although full neuropsychological testing may still be needed. © 2014 International Parkinson and Movement Disorder Society
-
validation of the italian version of the Movement Disorder society unified parkinson s disease rating scale
Neurological Sciences, 2013Co-Authors: Angelo Antonini, Glenn T. Stebbins, Christopher G. Goetz, Barbara C Tilley, Giovanni Abbruzzese, Luigi Ferinistrambi, Jing Huang, Paolo Barone, Monica Bandettini Di Poggio, Giovanni FabbriniAbstract:The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been available in English since 2008. As part of this process, the MDS-UPDRS organizing team developed guidelines for development of official non- English translations. We present here the formal process for completing officially approved non-English versions of the MDS-UPDRS and specifically focus on the first of these versions in Italian. The MDS-UPDRS was translated into Italian and tested in 377 native-Italian speaking PD patients. Confirmatory and exploratory factor analyses determined whether the factor structure for the English- language MDS-UPDRS could be confirmed in data col- lected using the Italian translation. To be designated an 'Official MDS translation,' the Comparative Fit Index (CFI) had to be C0.90 relative to the English-language version. For all four parts of the Italian MDS-UPDRS, the CFI, in comparison with the English-language data, was C0.94. Exploratory factor analyses revealed some differ- ences between the two datasets, however these differences were considered to be within an acceptable range. The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now avail- able for use. This protocol will serve as outline for further validation of this in multiple languages.
-
calibration of unified parkinson s disease rating scale scores to Movement Disorder society unified parkinson s disease rating scale scores
Movement Disorders, 2012Co-Authors: Christopher G. Goetz, Glenn T. Stebbins, Barbara C TilleyAbstract:The aim of this study was to develop formulas to convert the UPDRS to Movement Disorder Society (MDS)-UPDRS scores. The MDS-UPDRS is a revision of the UPDRS with sound clinimetric properties. Reliable formulas to recalculate UPDRS scores into MDS-UPDRS equivalents are pivotal to the practical transition and definitive adoption of the MDS-UPDRS. UPDRS and MDS-UPDRS scores were collected on 875 PD patients. A developmental sample was used to regress UPDRS scores on corresponding MDS-UPDRS scores based on three H & Y groupings (I/II, III, and IV/V). Regression weighting factors and intercept terms provided formulas for UPDRS conversions to be tested in a validation sample. Concordance between the true MDS-UPDRS Part scores and those derived from the formulas was compared using Bland-Altman's plots and Lin's concordance coefficient (LCC). Significant concordance between UPDRS-estimated MDS-UPDRS scores was achieved for Parts II (Motor Experiences of Daily Living) (LCC = 0.93) and III (Motor Examination) (LCC = 0.97). The formulas resulted in mean differences between the true MDS-UPDRS and estimated MDS-UPDRS scores of less than 1 point for both Parts II and III. Concordance was not achieved for Parts I and IV (Non-motor Experiences of Daily Living and Complications of Therapy). Formulas allow archival UPDRS Parts II and III individual patient data to be accurately transferred to MDS-UPDRS scores. Because Part I collects data on much more extensive information than the UPDRS, and because Part IV is structured differently in the two versions, old ratings for these parts cannot be converted. © 2012 Movement Disorder Society.
-
the Movement Disorder society evidence based medicine review update treatments for the non motor symptoms of parkinson s disease
Movement Disorders, 2011Co-Authors: Susan H Fox, Christopher G. Goetz, Werner Poewe, Olivier Rascol, Regina Katzenschlager, Shenyang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Cristina SampaioAbstract:The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treat- ments for PD with a focus on non-motor symptoms. Level-I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non-motor symptoms of PD, published as full
Richard J. Rodenburg - One of the best experts on this subject based on the ideXlab platform.
-
clpb mutations cause 3 methylglutaconic aciduria progressive brain atrophy intellectual disability congenital neutropenia cataracts Movement Disorder
American Journal of Human Genetics, 2015Co-Authors: Saskia B Wortmann, Szymon Zietkiewicz, Maria Kousi, Radek Szklarczyk, Tobias B Haack, Soren W Gersting, Ania C Muntau, Aleksandar Rakovic, Herma G Renkema, Richard J. RodenburgAbstract:We studied a group of individuals with elevated urinary excretion of 3-methylglutaconic acid, neutropenia that can develop into leukemia, a neurological phenotype ranging from nonprogressive intellectual disability to a prenatal encephalopathy with progressive brain atrophy, Movement Disorder, cataracts, and early death. Exome sequencing of two unrelated individuals and subsequent Sanger sequencing of 16 individuals with an overlapping phenotype identified a total of 14 rare, predicted deleterious alleles in CLPB in 14 individuals from 9 unrelated families. CLPB encodes caseinolytic peptidase B homolog ClpB, a member of the AAA+ protein family. To evaluate the relevance of CLPB in the pathogenesis of this syndrome, we developed a zebrafish model and an in vitro assay to measure ATPase activity. Suppression of clpb in zebrafish embryos induced a central nervous system phenotype that was consistent with cerebellar and cerebral atrophy that could be rescued by wild-type, but not mutant, human CLPB mRNA. Consistent with these data, the loss-of-function effect of one of the identified variants (c.1222A>G [p.Arg408Gly]) was supported further by in vitro evidence with the mutant peptides abolishing ATPase function. Additionally, we show that CLPB interacts biochemically with ATP2A2, known to be involved in apoptotic processes in severe congenital neutropenia (SCN) 3 (Kostmann disease [caused by HAX1 mutations]). Taken together, mutations in CLPB define a syndrome with intellectual disability, congenital neutropenia, progressive brain atrophy, Movement Disorder, cataracts, and 3-methylglutaconic aciduria.
Glenn T. Stebbins - One of the best experts on this subject based on the ideXlab platform.
-
Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing.
Movement Disorders, 2014Co-Authors: Brandon R. Barton, Bruno Dubois, Bryan Bernard, Virginie Czernecki, Jennifer G. Goldman, Glenn T. Stebbins, Christopher G. GoetzAbstract:The objective of our study was to compare Movement Disorder Society Task Force criteria for diagnosis of Parkinson's disease dementia (PDD) with the gold standard of traditional neuropsychological testing. A short checklist (Level I) and a protocol of neuropsychological tests (Level II) have been proposed by a Movement Disorder Society Task Force but not fully validated in clinical practice. Ninety-one Parkinson's disease (PD) subjects were categorized as having dementia or no dementia based on a battery of neuropsychological test results and clinical judgment. The isolated components needed for Level I and Level II diagnoses were then culled from the neuropsychological evaluations and independently used to designate PDD. Compared with traditional neuropsychological testing, the sensitivity and specificity of Level I criteria for PDD was 66.7% and 98.8%, and for Level II criteria 100% and 92.7%, respectively. Using Level II criteria, 6 additional subjects were diagnosed with PDD that were classified as having no dementia when full neuropsychological data were used for the diagnosis. These 6 subjects had more education years and were less impaired on cognitive tests. The Movement Disorder Society's Level II criteria more frequently classify subjects with PDD than does traditional neuropsychological testing. Whereas Level II criteria may overclassify subjects as having PDD, they are very accurate in ruling out dementia. Movement Disorder Society's criteria are practical and timesaving, although full neuropsychological testing may still be needed. © 2014 International Parkinson and Movement Disorder Society
-
validation of the italian version of the Movement Disorder society unified parkinson s disease rating scale
Neurological Sciences, 2013Co-Authors: Angelo Antonini, Glenn T. Stebbins, Christopher G. Goetz, Barbara C Tilley, Giovanni Abbruzzese, Luigi Ferinistrambi, Jing Huang, Paolo Barone, Monica Bandettini Di Poggio, Giovanni FabbriniAbstract:The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been available in English since 2008. As part of this process, the MDS-UPDRS organizing team developed guidelines for development of official non- English translations. We present here the formal process for completing officially approved non-English versions of the MDS-UPDRS and specifically focus on the first of these versions in Italian. The MDS-UPDRS was translated into Italian and tested in 377 native-Italian speaking PD patients. Confirmatory and exploratory factor analyses determined whether the factor structure for the English- language MDS-UPDRS could be confirmed in data col- lected using the Italian translation. To be designated an 'Official MDS translation,' the Comparative Fit Index (CFI) had to be C0.90 relative to the English-language version. For all four parts of the Italian MDS-UPDRS, the CFI, in comparison with the English-language data, was C0.94. Exploratory factor analyses revealed some differ- ences between the two datasets, however these differences were considered to be within an acceptable range. The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now avail- able for use. This protocol will serve as outline for further validation of this in multiple languages.
-
calibration of unified parkinson s disease rating scale scores to Movement Disorder society unified parkinson s disease rating scale scores
Movement Disorders, 2012Co-Authors: Christopher G. Goetz, Glenn T. Stebbins, Barbara C TilleyAbstract:The aim of this study was to develop formulas to convert the UPDRS to Movement Disorder Society (MDS)-UPDRS scores. The MDS-UPDRS is a revision of the UPDRS with sound clinimetric properties. Reliable formulas to recalculate UPDRS scores into MDS-UPDRS equivalents are pivotal to the practical transition and definitive adoption of the MDS-UPDRS. UPDRS and MDS-UPDRS scores were collected on 875 PD patients. A developmental sample was used to regress UPDRS scores on corresponding MDS-UPDRS scores based on three H & Y groupings (I/II, III, and IV/V). Regression weighting factors and intercept terms provided formulas for UPDRS conversions to be tested in a validation sample. Concordance between the true MDS-UPDRS Part scores and those derived from the formulas was compared using Bland-Altman's plots and Lin's concordance coefficient (LCC). Significant concordance between UPDRS-estimated MDS-UPDRS scores was achieved for Parts II (Motor Experiences of Daily Living) (LCC = 0.93) and III (Motor Examination) (LCC = 0.97). The formulas resulted in mean differences between the true MDS-UPDRS and estimated MDS-UPDRS scores of less than 1 point for both Parts II and III. Concordance was not achieved for Parts I and IV (Non-motor Experiences of Daily Living and Complications of Therapy). Formulas allow archival UPDRS Parts II and III individual patient data to be accurately transferred to MDS-UPDRS scores. Because Part I collects data on much more extensive information than the UPDRS, and because Part IV is structured differently in the two versions, old ratings for these parts cannot be converted. © 2012 Movement Disorder Society.
-
Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS).
Movement disorders : official journal of the Movement Disorder Society, 2010Co-Authors: Christopher G. Goetz, Glenn T. Stebbins, Teresa A. Chmura, Stanley Fahn, Werner Poewe, Caroline M. TannerAbstract:To accompany the newly developed Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), we developed a teaching program. The DVD-based program covers the four parts of the scale with visual and verbal instructions for uniform application. For the motor section (Part III), all items except rigidity are shown with an example of each rating option (0-4) as agreed upon by a panel of experts. The rate of agreement for the selected samples was always significant, with Kendall's coefficient of concordance W ranging between 0.99 and 0.72. The teaching program also provides a full patient examination with rating answers provided and four full MDS-UPDRS cases for a Certificate Program exercise of Part III. This training program is in English, but as non-English official translations of the MDS-UPDRS are developed, the program can be potentially modified into different languages.
-
Movement Disorder society sponsored revision of the unified parkinson s disease rating scale mds updrs scale presentation and clinimetric testing results
Movement Disorders, 2008Co-Authors: Christopher G. Goetz, Glenn T. Stebbins, Stanley Fahn, Werner Poewe, Barbara C Tilley, Stephanie R Shaftman, Pablo Martinezmartin, Cristina Sampaio, Matthew B Stern, Richard DodelAbstract:We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded the UPDRS using recommendations from a published critique. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor Complications. Twenty questions are completed by the patient/caregiver. Item-specific instructions and an appendix of complementary additional scales are provided. Movement Disorder specialists and study coordinators administered the UPDRS (55 items) and MDS-UPDRS (65 items) to 877 English speaking (78% non-Latino Caucasian) patients with Parkinson's disease from 39 sites. We compared the two scales using correlative techniques and factor analysis. The MDS-UPDRS showed high internal consistency (Cronbach's alpha = 0.79–0.93 across parts) and correlated with the original UPDRS (ρ = 0.96). MDS-UPDRS across-part correlations ranged from 0.22 to 0.66. Reliable factor structures for each part were obtained (comparative fit index > 0.90 for each part), which support the use of sum scores for each part in preference to a total score of all parts. The combined clinimetric results of this study support the validity of the MDS-UPDRS for rating PD. © 2008 Movement Disorder Society
Michael H. Silber - One of the best experts on this subject based on the ideXlab platform.
-
An update on the dopaminergic treatment of restless legs syndrome and periodic limb Movement Disorder.
Sleep, 2004Co-Authors: Wayne A. Hening, Richard P. Allen, Christopher J. Earley, Daniel L. Picchietti, Michael H. SilberAbstract:This paper reviews evidence from April, 1998 through April 2002 for the dopaminergic treatment of the restless legs syndrome (RLS) and periodic limb Movement Disorder (PLMD). There has been increased study of dopaminergic agents for the treatment of these conditions since publi- cation of a review paper and practice parameters that covered all types of medical treatment of RLS and PLMD in 1999. For this reason, the Restless Legs Syndrome Task Force and the Standards of Practice Committee decided to update the evidence on dopaminergic treatment of these condi- tions. This paper reviews the literature on levodopa, dopaminergic ago- nists (pergolide, pramipexole, ropinirole, talipexole, cabergoline, piribidel, DHEC), and other dopaminergic agents (amantadine, selegiline). Abbreviations: DB, double blinded; DHEC, alpha-dihydroergocryptine; F, female; ICSD- International Classification of Sleep Disorders (6); IRLSSG, diagnosis by International RLS Study group criteria (34); M, male; PD, Parkinson's disease; PLM, periodic limb Movement(s); PLMA, periodic limb Movements(s) with arousal; PLMAI, periodic limb Movement arousal index (PLMA per hour of sleep); PLMI, PLMS index (PLMS per hour of sleep); PSG, polysomnography (sleep study); QHS, nightly at bedtime; QOL, qual- ity of life; SBJ, subjective measure; SE, sleep efficiency; SR, sustained release (formulation of levodopa compound); TIB, time in bed; TX, therapy Citation: A Review by the Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syn- drome and periodic limb Movement Disorder. SLEEP 2004; 27(3):560-83.
-
an update on the dopaminergic treatment of restless legs syndrome and periodic limb Movement Disorder
Sleep, 2004Co-Authors: Wayne A. Hening, Richard P. Allen, Christopher J. Earley, Daniel L. Picchietti, Michael H. SilberAbstract:This paper reviews evidence from April, 1998 through April 2002 for the dopaminergic treatment of the restless legs syndrome (RLS) and periodic limb Movement Disorder (PLMD). There has been increased study of dopaminergic agents for the treatment of these conditions since publication of a review paper and practice parameters that covered all types of medical treatment of RLS and PLMD in 1999. For this reason, the Restless Legs Syndrome Task Force and the Standards of Practice Committee decided to update the evidence on dopaminergic treatment of these conditions. This paper reviews the literature on levodopa, dopaminergic agonists (pergolide, pramipexole, ropinirole, talipexole, cabergoline, piribidel, DHEC), and other dopaminergic agents (amantadine, selegiline).
Jonathan E Aviv - One of the best experts on this subject based on the ideXlab platform.
-
laryngeal sensory deficits in patients with chronic cough and paradoxical vocal fold Movement Disorder
Laryngoscope, 2010Co-Authors: Thomas Murry, Ryan C Branski, Sabrina Cukierblaj, Suzy Duflo, Jonathan E AvivAbstract:Objectives/Hypothesis: Although the diagnostic accuracy of paradoxical vocal fold Movement Disorder and chronic cough has improved, the underlying pathophysiology remains relatively unknown. We hypothesize that one potential etiological factor in these patients is an aberrant laryngeal sensory response and sought to determine if respiratory retraining in addition to antireflux therapy alters this aberrant response. Study Design: Retrospective, outcomes. Methods: Sixteen patients who had been on at least 3 months of twice-daily proton pump inhibitors with no subjective improvement in their primary complaint of cough, self-reported symptoms of gastroesophageal and laryngopharyngeal reflux, and concurrent paradoxical vocal fold Movement (PVFM) were included in the current study. In addition to continuing twice daily pharmacological therapy, subjects underwent a course of respiratory retraining. Outcome measures including the Reflux Symptom Index (RSI), transnasal flexible laryngoscopy, and laryngopharyngeal sensory discrimination thresholds were obtained prior to and following a course of respiratory retraining. Results: Mean bilateral laryngeal sensory response improved significantly after combined respiratory retraining and aggressive proton pump inhibitor therapy (P = .01). In addition, mean RSI score decreased significantly following treatment (P = .02). Specifically, 13 of 16 patients experienced improved sensory response, corresponding with patient reports of improved PVFM symptoms following treatment. Conclusions: Aberrant laryngeal sensation was identified in patients with PVFM and chronic cough. This response, however, normalized following a limited course of respiratory retraining, corresponding with improved patient symptoms. Laryngoscope, 2010
-
respiratory retraining of refractory cough and laryngopharyngeal reflux in patients with paradoxical vocal fold Movement Disorder
Laryngoscope, 2004Co-Authors: Thomas Murry, Abtin Tabaee, Jonathan E AvivAbstract:Objectives/Hypothesis: The objective was to describe a case series of patients with refractory cough and paradoxical vocal fold Movement Disorder treated with respiratory retraining therapy. Study Design: Retrospective review of a case series in a tertiary medical care center. Methods: Five patients with laryngopharyngeal reflux were identified with refractory cough and paradoxical fold Movement Disorder on transnasal fiberoptic laryngoscopy by a greater than 50% reduction in airway during inspiration. The were four women and one man (age range, 42–67 y). All patients had normal forced vital capacity and forced expiratory flow but decreased ratio of forced inspiratory volume at 0.5 seconds (FIV0.5) to forced inspiratory vital capacity (FIVC) before starting therapy. All patients were treated with more than 6 months of twice-daily proton pump inhibitor therapy with improvement in reflux symptoms but persistent and severe daytime cough. They were subsequently treated with respiratory retraining therapy. Patients were asked to rate subjectively the severity of cough at the onset and conclusion of therapy. All patients underwent pulmonary function testing before and after therapy. Long-term follow-up ranged from 5 to 17 months. Results: Patients received two to seven sessions of respiratory retraining therapy. The mean severity score changed from 9.2 before therapy to 1.3 after therapy. All patients subjectively described an improvement in the severity of their cough. Transnasal flexible laryngoscopy demonstrated improvement in paradoxical vocal fold Movement, and pulmonary function testing showed improvement in the FIV0.5/FIVC ratio. Conclusion: Patients with laryngopharyngeal reflux and refractory cough in the absence of pulmonary disease should be evaluated for paradoxical vocal fold Movement Disorder. Respiratory retraining therapy may represent an effective therapy for cough in the absence of relief from standard management of laryngopharyngeal reflux.
